ArticleVaccine2008
A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity.
Article in Vaccine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 75 citations in OpenAlex.
- Mucosal Vaccine Development: From Adjuvant Design to Next-Generation Delivery Strategies.Biomedicines · 2026Review
- Olfactory immunology: the missing piece in airway and CNS defence.Nature reviews. Immunology · 2024Review
- Article
- Review
- Cellular Basis for the Enhanced Efficacy of the Fms-Like Tyrosine Kinase 3 Ligand (FL) Adjuvanted VCG-BasedFrontiers in immunology · 2021Article
- Respiratory FimA-Specific Secretory IgA Antibodies Upregulated by DC-Targeting Nasal Double DNA Adjuvant Are Essential for Elimination ofFrontiers in immunology · 2021Article
- Nasal double DNA adjuvant induces salivary FimA-specific secretory IgA antibodies in young and aging mice and blocks Porphyromonas gingivalis binding to a salivary protein.BMC oral health · 2019Article
- Site-Specific DC Surface Signatures Influence CD4Frontiers in immunology · 2019Article
- Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems.Journal of immunology (Baltimore, Md. : 1950) · 2017Review
- Dendritic cell-targeting DNA-based nasal adjuvants for protective mucosal immunity to Streptococcus pneumoniae.Microbiology and immunology · 2017Review
- Rejuvenation of mucosal immunosenescence by adipose tissue-derived mesenchymal stem cells.International immunology · 2017Review
- Adipose-Derived Mesenchymal Stem Cells Restore Impaired Mucosal Immune Responses in Aged Mice.PloS one · 2016Article
- Phenotype and function of nasal dendritic cells.Mucosal immunology · 2015Article
- Innate endogenous adjuvants prime to desirable immune responses via mucosal routes.Protein & cell · 2015Review
- A molecular mucosal adjuvant to enhance immunity against pneumococcal infection in the elderly.Immune network · 2015Review
- Mucosal Immunosenescence in the Gastrointestinal Tract: A Mini-Review.Gerontology · 2015Review
- Vaccination with Toxoplasma lysate antigen and CpG oligodeoxynucleotides: comparison of immune responses in intranasal versus intramuscular administrations.Parasitology research · 2014Article
- Mucosal adjuvants for vaccines to control upper respiratory infections in the elderly.Experimental gerontology · 2014Review
- Mucosal dendritic cells shape mucosal immunity.Experimental & molecular medicine · 2014Review
- Enhancement of serum and mucosal immune responses to a Haemophilus influenzae Type B vaccine by intranasal delivery.Clinical and vaccine immunology : CVI · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 2 countries.
Funding
Abstract
We explore cellular and molecular mechanisms of nasal adjuvant of a combination of a plasmid encoding the Flt3 ligand cDNA (pFL) and CpG oligodeoxynucleotides (CpG ODN). The double DNA adjuvant given with OVA maintained prolonged OVA-specific secretory IgA (S-IgA) Ab responses in external secretions for more than 25 weeks after the final immunization. Further, both Th1- and Th2-type cytokine responses were induced by this combined adjuvant regimen. The frequencies of plasmacytoid DCs (pDCs) and CD8(+) DCs were significantly increased in nasopharyngeal-associated lymphoreticular tissue (NALT) of mice given the combined adjuvant. Importantly, when we examined adjuvanticity of pFL plus CpG ODN in 2-year-old mice, significant levels of mucosal IgA Ab responses were also induced. These results demonstrate that nasal delivery of a combined DNA adjuvant offers an attractive possibility for the development of an effective mucosal vaccine for the elderly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.